Chain Bridge I

Press Releases

SEC Filings

All Filings for Chain Bridge Available via EDGAR

View Filings

Our Team

Andrew Cohen, Chief Executive Officer

Andrew Cohen is our Chief Executive Officer and a Board Member. From January 2019 to September 2023 Mr. Cohen was a Founder and the CIO of Difesa Capital Management, a special situations fund focused on convertible bonds, SPAC securities, PIPEs, warrants and public equities. Prior to launching Difesa, Mr. Cohen worked at Ramius from 2001 to 2018. Ramius was a $13 billion multi-strategy hedge fund that ultimately merged with the investment bank Cowen in 2009. While at Ramius Mr. Cohen worked across a range of investment strategies including merger arbitrage, event driven, small cap equity activism, and distressed debt. Most recently, Mr. Cohen was one of two partners overseeing the Ramius Event Driven and Merger Arbitrage business within Cowen Investment Management. From 2011 to 2018, Mr. Cohen co-founded and operated a nine-person team investing Cowen proprietary capital and fiduciary assets in merger arbitrage and event driven strategies. During his time with the firm the Ramius Merger Fund LLC had peak assets of $500 million and the Merrill Lynch Investment Solutions / Ramius Merger Arbitrage UCITS Fund had peak assets of $250 million. Prior to joining Ramius, Mr. Cohen worked as an analyst in the investment banking and private equity groups at Thomas Weisel Partners. Mr. Cohen received a B.A. in Public Policy from the Terry Sanford Institute at Duke University and an MBA from Columbia Business School.

Andrew “Al” Kucharchuk, Chief Financial Officer

Mr. Kucharchuk was appointed as CFO of Chain Bridge I effective April 4, 2024. Mr Kucharchuk has served as the Chief Financial Officer of Theralink Technologies, Inc. (“Theralink”) (OTCMKTS: THER) since May 2023. Previously, he also served as President and Chief Financial Officer of Theralink from February 2016 until June 2020, as Chief Executive Officer of Theralink from November 2019 until June 2020 and as Acting Chief Financial Officer of Theralink from June 2020 to September 2020. He has served on the Board of Directors of Theralink since June 2020. Mr. Kucharchuk also served as Chief Executive Officer and Chief Financial Officer of OncBioMune, Inc. (“OBMP”) prior to Theralink’s acquisition of OBMP. Mr. Kucharchuk served as the Chairman and Chief Operating Officer Adhera Therapeutics, Inc. (OTCMKTS: ATRX) from July 2020 until September 2022 and its Chief Operations Officer from October 2022 to Present. Mr. Kucharchuk is a graduate of Louisiana State University and Tulane University’s Freeman School of Business, where he earned an MBA with a Finance Concentration.

Financial and Tax Disclosures

Download item year list 2024 2023
Date Download Description

Stock Quote

Historical Stock Quote